Engaging the Natural Killer Cells for Potent Anticancer Effect

SAUVIE



Disclaimer

IMPORTANT: YOU MUST READ THE FOLLOWING BEFORE CONTINUING

The information contained in this presentation has been prepared by Sauvie Inc. ("**Sauvie**" or the "**Company**") and contains information pertaining to the business, operations and assets of the Company. The information contained in this presentation (a) is provided as at the date hereof and is subject to change without notice, (b) does not purport to contain all the information that may be necessary or desirable to fully and accurately evaluate an investment in the Company and (c) is not to be considered as a recommendation by the Company that any person make an investment in the Company. The Company and its respective subsidiaries and affiliates, and any of its respective shareholders, directors, officers, agents, consultants, advisors or employees do not make any representation or warranty, express or implied, as to the accuracy, completeness or thoroughness of the information contained in this presentation.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION: This presentation includes information, statements, beliefs and opinions which are forward-looking, and which reflect current estimates, expectations and projections about future events. Statements containing the words "believe", "expect", "intend", "should", "seek", "anticipate", "will", "positioned", "project", "risk", "plan", "may", "estimate" or, in each case, their negative and words of similar meaning are intended to identify forward-looking information. By its nature, forward-looking information involves a number of known and unknown risks, uncertainties and assumptions concerning, among other things, the Company's anticipated business strategies, expectations with respect to applicable tax rates, anticipated trends in the Company's business, clinical development, anticipated future revenue streams, and anticipated market share, that could cause actual results or events to differ materially from those expressed or implied by such forward- looking information. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. In addition, even if the outcome and financial effects of the plans and events described herein are consistent with the forward-looking information contained in this presentation, those results or developments may not be indicative of results or developments in subsequent periods. Although the Company has attempted to identify important risks and factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors and risks that cause actions, events or results not to be as anticipated, estimated or intended. Forward-looking information contained in this presentation is based on the Company's current estimates, assumptions, expectations and projections, which the Company believes are reasonable as of the current date. The Company can give no assurance that these estimates, assumptions, expectations and projections will prove to have been correct. You should not place undue reliance on forward-looking information contained in this presentation. Forward-looking statements contained in this presentation are made of the date of this presentation and, except as required by applicable law, the Company assumes no obligation to update or revise them to reflect new events or circumstances. Historical information contained in this presentation regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. In this regard, certain financial information contained herein has been extracted from, or based upon, information available in the public domain and/or provided to the Company. In particular historical results should not be taken as a representation that such trends will be replicated in the future. No statement in this presentation is intended to be nor may be construed as a profit forecast. All forward-looking information in this presentation is expressly qualified in its entirety by this cautionary statement.

This presentation may have been sent to you in an electronic form. You are reminded that documents transmitted via this medium may be altered or changed during the process of electronic transmission. You are responsible for protecting against viruses and other destructive items. Your receipt of this electronic transmission is at your own risk and it is your responsibility to take precautions to ensure that it is free from viruses and other items of a destructive nature. As a consequence of the above, neither the Company nor any director, officer, employee or agent of any of them or any affiliate of any such person accepts any liability or responsibility whatsoever in respect of any difference between the presentation distributed to you in electronic format and the hard copy version that may be made available to you.

Sauvie Inc. Snapshot

- Sauvie Inc. ("Sauvie") is a mission-driven oncology company executing a **diversified risk**, high growth strategy in development and commercialization.
- Management team has deep development and commercialization experience and multiple successes in oncology.
- Privately held, formed in 2022 with offices in Short Hills, NJ.



- Fully controlled subsidiary Sauvie BiKE, LLC signed exclusive license with Rutgers University to develop and commercialize the bi-specific NK cell engager (BiKE)
- Raise seed capital to conduct inaugural in vivo study

History


• Sauvie Inc. formed
• Successfully closed pre-seed round – completed $165,000 raise
• Formed Sauvie BiKE, LLC
• Converted provisional patents (composition & method) to USPTO and PCT applications
• In vitro study results published in *Frontiers in Immunology*
• Launch seed round
May
Jul
Sep
Oct
Dec
Jan '23
Mar '23
• Launched pre-seed round
• Sauvie BiKE, LLC signs exclusive license to develop and commercialize BiKE platform in oncology
• Secured manufacturer and initiated production of clinical batch
• Submitted NIH grant application
• CRO selected for 1) PBMC donor screening study and 2) inaugural in vivo study

What's in a Name?

The French phrase "sauver une vie" means "to save a life"

We created Sauvie Inc, to embody this spirit in everything we do

Highly Accomplished Team

To govern and execute on Sauvie's mission

John Canan
Chairman

Scott Oehrlein
Board Director

Ken Suh
CEO, Exec Board Dir.

Brian E. Jahns
C. Operating Officer

Audrey Haukioja
C. Dev. Officer

Dr. Bob Uger
Scientific Advisor

Dr. Albert Agro
Scientific Advisor

- Combined +150 years of experience
- Multiple start ups and exits
- Private and public company executive leadership
- Oncology commercialization and development

Herceptin trastuzumab 21 mg/mL INJECTION FOR INTRAVENOUS USE

PERJETA pertuzumab 420 mg INJECTION FOR INTRAVENOUS USE

AFINITOR (everolimus) tablets

Rituxan Rituximab

AVASTIN bevacizumab 100 MG/4 ML INJECTION FOR IV USE

KEYTRUDA (pembrolizumab) Injection 100 mg

GARDASIL 9 Human Papillomavirus 9-valent Vaccine, Recombinant

Sandostatin LAR Depot (octreotide acetate) for injectable suspension 10mg 20mg 30mg

NOVARTIS

MERCK

Roche

Genentech A Member of the Roche Group

TRILLIUM THERAPEUTICS INC.

https://sauvieinc.com/team/ for full bios

Highlight of Team's Success and Approach

Commercial and Development Experience

Operational wins in both start-up and big pharma environments

High Quality Execution

Disciplined approach to high quality planning and execution

Global View

Global lens to bring critical therapies to market

Integrity and Reputation

Operating with highest ethical standards

Sustainable Growth

Seek revenue opportunities for sustainable growth

Diversified Risk

Multiple shots on net investment platform

Science and Operations Drive Our Strategy

We follow the science to bring critical cancer therapies to patients and be pragmatic to execute the strategy

Value	Pipeline	Sustainability
Drive near-term value with BiKE	Enhance pipeline via R&D and strategic acquisitions	Build a sustainable business through partnerships

Cancer Patients Continue to Suffer

Repeated relapses mean that patients struggle

- Deaths due to cancer continues to be the leading cause of death – 9.9 million deaths globally in 2020*
- Despite new cancer therapies, **patients grapple with relapse and disease recurrence**
- **~70% of ovarian cancer patients experience a relapse** in disease following an initial response to treatment despite antibody therapy
- **~30% of breast cancer patients experience a relapse** in disease following an initial response to treatment despite antibody therapy
- Immune escape is an important hallmark of cancer leading to tumor progression and metastasis**
- Antibody Drug Conjugates (ADC) are an option in disease recurrence, but potent conjugate payloads lead to significant cumulative toxicity
- Anti-PD1 antibodies provide frequent complete and partial responses, over varying duration. And current immunotherapies are limited by systemic toxicity

* World Health Organization

**Wu et al. Molecular Cancer (2020) 19:120

Sauvie's Solution – Bispecific Camelid Nanobody

The bispecific camelid nanobody platform (BiKE) engages the natural killer cells (CD16a) and HER2 tumor antigen for a potent anticancer effect with reduced toxicity



Comparison of Technologies

BiKE nanobody	BiTE nanobody (Tandem scFc)	Monocloncal antibody (mAb)	Antibody-drug conjugate (ADC)	CAR-T cell
• Camelid heavy chain antibody VHH fragments joined with semi-rigid linker, one targeting CD16a on NK cells, and the other targeting a tumor antigen • High affinity and high specificity to CD16a • Negligible cross-reactivity with CD16b-NA1 or CD32b	• Recombinant fusion protein comprised of two tandem scFv, one targeting CD3 on T cells, and the other targeting a tumor antigen, joined by a linker • Serious T-cell-related toxicities	• Engineered or naturally occurring antibody targeting cancer cell epitope of immune checkpoint • Tumor-infiltrating T-cell, and Immune checkpoint dependent • MHC and TCR dependent • Low affinity and low specificity to CD16a • Immunogenic • Cross-reactive to CD16b-NA1 and CD32b	• Monoclonal antibody conjugated to cytotoxic payload • Risk of systemic toxicity from conjugated toxin • Tumor-infiltrating T-cell dependent • Immune checkpoint dependent • MHC and TCR dependent • Low affinity and low specificity for CD16a • Immunogenic	• Recombinantly modified human immune cell • Serious immune-related toxicities • Antigen-dependent
~30 kD	~30-60 kD	~150 kD	~160 kD	Very large; approx. 5-7 µm
				

Bi-specific nanobody activates NK cells

10^2 to 10^3-fold more potent than trastuzumab, *in vitro*

BiKE activates NK cells by binding to CD16a



Lead program targets HER2 tumor antigen



Overview of SV-0420

BiKE activates NK cells at picomolar concentrations



Source: Nikkhoi SK., et al. Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy Frontiers in Immunology 2023. DOI 10.3389/fimmu.2022.1039969

Overview of SV-0420

Potentiates release of cytotoxic proteins and cytokines



Substantially higher release of cytotoxic proteins and cytokines than trastuzumab

Source: Nikkhoi SK., et al. Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy Frontiers in Immunology 2023. DOI 10.3389/fimmu.2022.1039969

Overview of SV-0420

In-vitro model of JIMT-1 breast ductal adenocarcinoma



Measurement of ADCC in JIMT-1 cancer cell lines using laNK92 cells in combination with BiKE or trastuzumab at different antibody concentrations but fixed E:T ratio of 4. This figure shows that BiKE induced >100 fold higher ADCC in comparison to trastuzumab

Source: Nikkhoi SK., et al. Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy Frontiers in Immunology 2023. DOI 10.3389/fimmu.2022.1039969

Overview of SV-0420

In-vitro model of BT474 breast ductal adenocarcinoma



Measurement of ADCC in BT474 cancer cell lines using laNK92 cells in combination with BiKE or trastuzumab at different antibody concentrations but fixed E:T ratio of 4. This figure shows that BiKE induced >100 fold higher ADCC in comparison to trastuzumab

Source: Nikkhoi SK., et al. Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy Frontiers in Immunology 2023. DOI 10.3389/fimmu.2022.1039969

Overview of SV-0420

In-vitro model of SKOV-3 ovarian adenocarcinoma



Measurement of ADCC in SKOV-3 cancer cell lines using laNK92 cells in combination with BiKE or trastuzumab at different antibody concentrations but fixed E:T ratio of 4. This figure shows that BiKE induced >100 fold higher ADCC in comparison to trastuzumab

Source: Nikkhoi SK., et al. Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy Frontiers in Immunology 2023. DOI 10.3389/fimmu.2022.1039969

Overview of SV-0420

BiKE kills cancer cells significantly better than trastuzumab

In vitro results published in *Frontiers in Immunology* on January 6th, 2023 with compelling data to support significant potential of BiKE platform



frontiers | Frontiers in Immunology

Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy

Shahryar Khoshtinat Nikkhoi[1], Geng Li[1], Suha Eleya[1], Ge Yang[1], Venu Gopal Vandavasi[2] and Arash Hatefi[1,3]*

[1]Department of Pharmaceutics, Rutgers University, Piscataway, NJ, United States, [2]Department of Chemistry, Biophysics Core Facility, Princeton University, Princeton, NJ, United States, [3]Cancer Pharmacology Program, Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ, United States

TYPE Original Research
PUBLISHED 06 January 2023
DOI 10.3389/fimmu.2022.1039969

- Induces significantly higher cancer cell death than gold standard therapy trastuzumab
- >100-fold more potent than trastuzumab
- Recognizes a different epitope on CD16a than IgG-based mAbs – thus provides opportunity for either monotherapy or combination therapy

Comparing other NK Engagers

Power in simplicity



StitchMab bispecific antibody
(Compass Therapeutics)



Multi-specific antibodies
(Cytovia Therapeutics)

Bispecific CD16a (Sauvie Inc)

Tri-specific
NKp46/CD16a
(Innate Pharma)



Tetravalent bi-specific
(Affimed GmbH)

Tri-specific
IL15a/CD16a
(GT Biopharma Inc)

NK and T-cell engager
(Dragonfly Therapeutics)

- Antibody associated immunogenicity
- Potential NK fratricide resulting from NK cell crosslinking
- Binding to CD16B
- IgG binding competition



- Unknown importance of IL15a in enhancing cytotoxicity
- Co-stimulation of NKp30 or NKp46 importance in drug action poorly understood
- Potential NK cell fratricide resulting from co-engagement of NKp46/CD16A and NKp30/CD16A

Development Strategy

Maximizing the potential of the platform

Monotherapy in HER2+ solid tumors in orphan indications

Combination with other oncology therapies in HER2+ tumors in orphan indications

Expand into more prevalent HER2+ tumor types

Expand platform to target other tumor antigens beyond HER2

BiKE Addresses Large Markets

Potential to be used alone or in combination with leading products

BiKE's initial focus is HER2+ tumors (breast, gastric, ovarian, endometrial, pancreatic)

Breast and gastric cancers

Herceptin (trastuzumab) >$7 billion annually

Roche

Breast cancer in combination with trastuzumab

Perjeta (pertuzumab) >$4 billion annually

Roche

10 oncology indications

Keytruda (pembrolizumab) >$20 billion annually

MERCK

BiKE has potential to address more indications similar to Keytruda and has potential to be used in combination

*From annual reports

Examples of Recent NK Engager License Deals

Highlights value of NK cell engagers and I/O

Innovator	Affimed	Innate Pharma	Dragonfly Therapeutics
Licensee(s)	Genentech, Roivant Sciences	Sanofi, AstraZeneca, Takeda	Abbvie, BMS, Gilead, Merck
Deal Type	Discovery and preclinical research (Opt-ins)	Discovery and preclinical research (Opt-ins)	Discovery and preclinical research (Opt-ins)
Key Deal Terms	Roivant (in 2020): **$60 million** upfront considerations and up to an additional **$2 billion** in future milestones. Genentech (in 2018): **$96 million** upfront and up to **$5 billion** in milestone payments plus royalties on sales	Sanofi (in 2022 to expand collaboration from 2016): **€25 million upfront payment** and up to **€1.35 billion total milestones**	Total of all deals: **$800 million in upfronts and early milestones**. Eligible for up to **$17 billion in total milestones**
Technology	Roivant: AFM32, Genentech: various	B7H3 ANKET plus option to add two additional targets	Various hematologic and solid tumors with TriNKET®

Seed Capital to Advance Program

Tranches to achieve milestones





Potential tax credit eligibility for angel investors:

1. NJ Angel Investor Tax Credit Program (regardless of residency in or out of NJ or U.S.) and up to 20% of investment amount within tax year
2. QSBS (Federal program on future capital gains)

Build non-GLP Data Package in 2023

Launch Series A in 2024



Capital uses:

- Non-GLP in vivo studies
- Working capital

Series A Launch and IND Studies in 2024

Series A: $25M

Launch IND enabling tox studies and GMP validation (~16 months)

Explore additional tumor targets (discovery and in vitro)

Capital uses:

- GLP in vivo studies and GMP validation
- Working capital

Seed to Series A

Multiple near term value inflection points for seed investors

Round	Shares	Capital	Price/Type	Comments	Pre-Money
Pre-seed	11,725,000 (O/S)	$165,000	$0.10/common	Raised prior to Sauvie signing exclusive license	~$1 million
Seed*	2,000,000	$600,000	$0.30/preferred	Current raise	~$3.5 million
Seed 2*	TBD	$800,000	TBD/preferred	Launch post in vivo results	TBD

*Forecast and for illustration purposes only based on market assumptions

Anticipated Series A pre-money valuation range: $20M to $28M**

**Estimate based on analysis by 3rd party

Summary

Sauvie Inc., is an emerging global biopharma company executing a diversified risk, high growth strategy

Capabilities and experience in place to build a premier oncology company

Development and Commercialization focus to deliver high-impact cancer medicines

Multiple shots on goal approach with high potential assets

Well structured and positioned to attract top biopharma talent

Ken Suh
CEO
ksuh@sauvieinc.com

Thank you

SAUVIE

www.sauvieinc.com